Cingulate

Cingulate Financing Cash Flow

The Net Financing Cash Flow of Cingulate (CING) as of Nov 11, 2026 is 16.15 M USD. In the previous year, Net Financing Cash Flow was 30.82 M USD — a change of -47.61% (lower).

Financing Cash Flow

16.15 MUSD

YoY

-47.61%

Last updated:

Net Financing Cash Flow of Cingulate is 2025 16.15 M USD. Net Financing Cash Flow of Cingulate was 2024 30.82 M USD. It decreases by -47.61% lower compared to the previous year.

The Cingulate Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2019
6.14 M USD
Jan 1, 2020
7.97 M USD
Jan 1, 2021
26.54 M USD
Jan 1, 2022
4.90 M USD
Jan 1, 2023
9.95 M USD
Jan 1, 2024
30.82 M USD
Jan 1, 2025
16.15 M USD
The Cingulate Financing Cash Flow history
YEARFinancing Cash FlowYoY
16.15 MUSD-47.61%
30.82 MUSD+209.62%
9.95 MUSD+103.20%
4.90 MUSD-81.54%
26.54 MUSD+232.85%
7.97 MUSD+29.77%
6.14 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cingulate Stock analysis

What does Cingulate do? Cingulate Inc is a US-based biopharmaceutical company headquartered in Kansas City, Kansas, that focuses on the development, manufacturing, and commercialization of pharmaceutical products. The firm utilizes its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles designed to improve the lives of patients suffering from commonly diagnosed conditions. The company specifically targets the treatment of attention deficit/hyperactivity disorder (ADHD) through its innovative approach to drug delivery. The firm is currently developing two lead product candidates, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). These drug candidates both contain three releases of an active pharmaceutical ingredient combined into one small tablet dosage form. By employing this technology, Cingulate Inc aims to provide effective treatment options for ADHD across three core patient segments: children aged 6-12, adolescents aged 13-17, and adults aged 18 and older. Cingulate is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cingulate stock

Net Financing Cash Flow of Cingulate is 16.15 M USD in 2025.

Net Financing Cash Flow of Cingulate changed from 30.82 M USD to 16.15 M USD, representing a -47.61% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Cingulate since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Cingulate historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Cingulate

All Key Metrics — Cingulate